We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Could pentraxin-3 be a new marker for subclinical inflammation in familial Mediterranean fever?
© Yüksel et al. 2015
- Published: 28 September 2015
- White Blood Cell
- Erythrocyte Sedimentation Rate
- Healthy Child
- Familial Mediterranean Fever
Pentraxin-3 (PTX-3) is a long pentraxin that is structurally related to the short pentraxins as C-reactive protein (CRP). It is known to play an important role in innate immunity and inflammatory regulation. CRP and serum amyloid A (SAA) are sensitive and reliable markers of inflammation in FMF attack as well as chronic and subclinical inflammation during attack-free period. To date, there is no information about PTX-3 in FMF inflammation.
The aim of the study was to investigate the progress of serum PTX-3 levels together with traditional acute phase reactants in FMF patients during attack and attack free period (two weeks after the attack) and also assess whether PTX-3 could be related with subclinical inflammation.
A prospective cross-sectional study was conducted between June 2013 and July 2014. A total of 45 consecutive children with FMF who were diagnosed according to the Tel-Hashomer and Yalçınkaya criteria were enrolled during the attack period. Blood samples were obtained from the patients during attack and attack free period (two weeks after the attack) and healthy children who were matched in terms of age and sex.
During Attack (Mean±SD)
After Attack (Mean±SD)
WBC (x10 9 /L)
CRP (mg/dL) (normal: 0-1)
ESR (mm/hour) (normal < 20)
Fibrinogen (mg/dL) (normal: 180-350)
SAA (mg/L) (normal: 0-7)
Serum PTX-3 levels increased during the attacks of FMF and decreased during the attack free period however mean level of it was still higher than healthy subjects. We suggest that PTX-3 might be a new marker for both attack period and subclinical inflammation in FMF patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.